A study of Greater Occipital Nerve Blockade for the preventive treatment of Chronic Migraine
Not Applicable
- Conditions
- Health Condition 1: G437- Chronic migraine without aura
- Registration Number
- CTRI/2020/07/026709
- Lead Sponsor
- GB Pant hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
Any patient above 18 years and less than 65 years of age who fulfills the diagnostic criteria laid down by ICHD 3 for Chronic Migraine( with or without aura) and willing to give consent will be included.
Exclusion Criteria
All patients with a clinical phenotype of chronic migraine but on further investigation, found to have a secondary cause for their headaches will be excluded. Pregnant women, patient with known allergies against topiramate or lidocaine, patients with history of glaucoma, renal stones, dementia, psychosis and severe depression shall be excluded from the study.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method 1.Change in headache days per 28 days (Headache day is defined as a calendar day [00:00 to 23:59] when the patient reported â?¥4 continuous hours of headache episode in the diary)Timepoint: for double blind phase primary and secondary outcome will be assessed at the end of 4 weeks after first GONB injection. Final assessment of efficacy including primary and secondary outcomes shall be carried out at end of 12 weeks and results shall be compared with the baseline. <br/ ><br>For open label phase primary and secondary outcomes shall be assessed at the end of 24 weeks.
- Secondary Outcome Measures
Name Time Method